Literature DB >> 3183945

A radioimmunoassay for pyridostigmine.

H G Meyer1, B J Lukey, R T Gepp, R P Corpuz, C N Lieske.   

Abstract

Antipyridostigmine antibodies were produced in rabbits using a pyridostigmine analog conjugated to keyhole limpet hemocyanin. These antibodies were used for development of a radioimmunoassay that has a linear standard curve (r2 = 0.986) ranging from 0.5 to 10.0 ng/ml of pyridostigmine bromide in a 0.1-ml plasma sample. This assay measures pyridostigmine in plasma with better sensitivity and much greater through-put than do current state-of-the-art high-performance liquid chromatography techniques. In addition, only small volumes (100 microliter) of the plasma samples are required. Plasma levels of pyridostigmine were determined in the rat after intramuscular administration (0.056 mg/kg) of pyridostigmine bromide. Estimates of the various pharmacokinetic parameters were calculated using the computer program NONLIN84. The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183945

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Persistent exercise fatigue and associative learning deficits in combination with transient glucose dyshomeostasis in a mouse model of Gulf War Illness.

Authors:  Elena V Kozlova; Bruno Carabelli; Anthony E Bishay; Maximillian E Denys; Devi B Chinthirla; Jasmin D Tran; Ansel Hsiao; Nicole I Zur Nieden; Margarita C Currás-Collazo
Journal:  Life Sci       Date:  2021-10-26       Impact factor: 6.780

2.  Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings.

Authors:  Kamil Kuca; Jana Zdarova Karasova; Ondrej Soukup; Jiri Kassa; Eva Novotna; Vendula Sepsova; Anna Horova; Jaroslav Pejchal; Martina Hrabinova; Eva Vodakova; Daniel Jun; Eugenie Nepovimova; Martin Valis; Kamil Musilek
Journal:  Drug Des Devel Ther       Date:  2018-03-09       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.